Physician profile
Sandesh Jain
NPI 1831236967
$1,794.20
in general payments reported to CMS, 2019-2025
21 companies · $363 in 2025
The $363 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $258 · 2020: $277 · 2021: $180 · 2022: $271 · 2023: $229 · 2024: $217 · 2025: $363.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $806 · Education: $3.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $805.81 |
| Education | $3.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $355.21 | 2019-2023 | Veltassa |
| Amgen INC. | $348.93 | 2019-2025 | Tavneos, Krystexxa, Aranesp |
| Baxter Healthcare | $191.86 | 2022-2023 | Renal - Pd |
| Astrazeneca Pharmaceuticals LP | $124.66 | 2019-2023 | Farxiga, Lokelma |
| Fresenius USA Marketing, INC. | $98.91 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $86.11 | 2021-2025 | |
| Glaxosmithkline, LLC. | $72.23 | 2020-2024 | Benlysta, Jesduvroq |
| Horizon Therapeutics Plc | $69.07 | 2019-2023 | Krystexxa |
| Ardelyx, INC. | $64.37 | 2024-2025 | Ibsrela |
| Opko Pharmaceuticals, LLC | $53.91 | 2019-2020 | |
| Calliditas Therapeutics US INC. | $44.80 | 2024-2025 | Tarpeyo |
| Amarin Pharma, INC. | $41.84 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $40.98 | 2023-2025 | |
| Ani Pharmaceuticals, INC. | $40.47 | 2022-2024 | Purified Cortrophin Gel |
| Daiichi Sankyo INC. | $27.39 | 2020-2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $26.93 | 2019-2025 | Vafseo |
| Aurinia Pharma U.S., INC. | $26.90 | 2021-2025 | Lupkynis |
| Otsuka America Pharmaceutical, INC. | $26.83 | 2020-2025 | Jynarque |
| Travere Therapeutics, INC. | $26.02 | 2023-2024 | |
| Kyowa Kirin, INC. | $13.55 | 2024 | Crysvita |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $13.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandesh Jain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.